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Intravenous KITENIN shRNA Injection Suppresses Hepatic 
Metastasis and Recurrence of Colon Cancer in an Orthotopic 
Mouse Model
KITENIN (KAI1 C-terminal interacting tetraspanin) promotes invasion and metastasis in 
mouse colon cancer models. In the present study, we evaluated the effects of KITENIN 
knockdown by intravenous administration of short hairpin RNAs (shRNAs) in an orthotopic 
mouse colon cancer model, simulating a primary or adjuvant treatment setting. We 
established orthotopic models for colon cancer using BALB/c mice and firefly luciferase-
expressing CT-26 (CT26/Fluc) cells. Tumor progression and response to therapy were 
monitored by bioluminescence imaging (BLI). In the primary therapy model, treatment 
with KITENIN shRNA substantially delayed tumor growth (P = 0.028) and reduced the 
incidence of hepatic metastasis (P = 0.046). In the adjuvant therapy model, KITENIN 
shRNA significantly reduced the extent of tumor recurrence (P = 0.044). Mice treated with 
KITENIN shRNA showed a better survival tendency than the control mice (P = 0.074). Our 
results suggest that shRNA targeting KITENIN has the potential to be an effective tool for 
the treatment of colon cancer in both adjuvant and metastatic setting.
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INTRODUCTION
KAI1 encodes a transmembrane glycoprotein of the tetraspanin 
family and was initially described as a prostate-specific metas-
tasis suppressor (1-3). Down-regulation or loss of KAI1 expres-
sion occurs in advanced stages of many types of human cancer 
and is associated with poor prognosis, leading to the proposal 
that KAI1 might be a metastasis suppressor (4-12).
  Previously, we cloned KITENIN (KAI1 C-terminal interacting 
tetraspanin), a member of the tetraspanin protein family that 
interacts specifically with the C-terminal cytoplasmic domain of 
KAI1 (13). In contrast to KAI1, KITENIN increases migration and 
invasiveness of colon cancer cells and knockdown of KITENIN 
inhibits tumor metastasis in a mouse colon cancer model (13-
15). Recently, we reported the signaling mechanism of KITENIN 
at cellular level. KITENIN serves as a scaffolding molecule that 
simultaneously recruits both Dishevelled (Dvl) and protein ki-
nase Cδ (PKCδ) through the membrane-spanning C-terminal 
region to form a complex that stimulates extracellular signal-reg-
ulated kinase (ERK)/activating protein-1 (AP-1) via a PKCδ com-
ponent but also organizes the actin filament via a Dvl compo-
nent (15). KITENIN knockdown distorts the actin arrangement 
and decreases AP-1 target genes such as MMP-1, MMP-3 and 
CD44, thereby suppresses tumor cell invasion and metastasis 
(15). These results suggest that the knockdown of KITENIN could 
be useful for the treatment of colon cancer together with other 
chemotherapeutic agents.
  The current study was designed to investigate the systemic 
effects of KITENIN knockdown on a clinically relevant orthotop-
ic mouse colon cancer model, simulating a primary treatment 
or adjuvant setting. 
 
MATERIALS AND METHODS
KITENIN shRNA expression plasmids
To silence the expression of KITENIN, five regions of mouse KIT-
ENIN were targeted for small interfering RNAs (siRNAs). Two of 
the five regions were shown to specifically reduce the expression 
of mouse KITENIN (KITENIN S2, 5´-GCGCTATCTGGGCCT-
TACC-3´; KITENIN S5, 5´-AGAAGCGGAGAGCAAGACT-3´). To 
generate siRNAs, equimolar amounts of complementary sense 
and antisense strands were each mixed and annealed in a 50 μL 
reaction at 90°C for 4 min, 70°C for 10 min, 60°C for 30 min, 37°C 
for 20 min, and 25°C for 10 min. The pSUPER vector (OligoEn-Hwang J-E, et al.  •  KITENIN shRNA Therapy in Orthotopic Mouse Colon Cancer Model
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gine, Seattle, WA, USA) was digested with BglII and HindIII and 
the annealed oligos were ligated into the vector to express short 
hairpin RNAs (shRNAs), which are processed in vivo as siRNA-
like molecules capable of carrying out gene-specific silencing. 
The sequences of the inserts in the two resulting shRNA expres-
sion plasmids, KITENIN shRNA2 and KITENIN shRNA5, were 
determined and no errors were found. 
Mice and tumor cell lines
BALB/c mice (5-7 weeks of age) were obtained from Jungang 
Lab Animal, Inc. (Seoul, Korea) and kept in our laboratory ani-
mal facility, maintained at 23°C ± 2°C with a relative humidity 
of 50% ± 20% and a 12-hour light/dark cycle. All methods used 
in this study (2010-3) were approved by the institutional animal 
care and use committee at the Chonnam National University 
Medical School Research Institution and conformed to NIH 
guidelines (NIH publication No. 86-23, revised 1985). The mu-
rine BALB/c-derived colon carcinoma cell lines, CT-26 and fire-
fly luciferase-expressing CT-26 (CT26/Fluc) cells were kindly 
provided by Dr. Min JJ (Chonnam National University, Korea). 
Imaging of live mice
The IVIS200 imaging system (Xenogen, Alameda, CA, USA), 
which included an optical charge-coupled device (CCD) cam-
era mounted on a light-tight specimen chamber, was used for 
data acquisition and analysis. Firefly D-luciferin potassium salt, 
the Fluc substrate, was diluted to 3 mg/100 μL in PBS before use. 
The mice were intraperitoneally injected with 100 μL of this D-
luciferin solution. Each mouse was placed in a specimen cham-
ber mounted with a CCD camera, which had been cooled to 
-105°C and whose field of view (FOV) was set to 26 cm above the 
sample shelf. Light emitted by luciferase in the mice was then 
measured. Gray scale photographic images and bioluminescent 
color images were superimposed using LIVINGIMAGE V. 2.12 
software (Xenogen) and IGOR image analysis software. Biolumi-
nescence signals are expressed in units of photons per second 
per centimeter squared per steradian (p/s/cm
2/sr). Background 
signal intensity in vivo was in the range of 1-3 × 10
5 photons/sec.
Primary therapy model
Subcutaneous xenografts were established by injecting firefly 
luciferase-expressing CT-26 (CT26/Fluc) cells (1 × 10
6 cells per 
mouse) into the right flank of BALB/c mice, and growth was mon-
itored regularly. Tumors were selected for orthotopic implanta-
tion at an average size of 1 cm
3 and the tissue was cut into 1.5 
mm
3 pieces. Implantation was performed according to the meth-
od described by Pocard and colleagues with some modifications 
(16). In brief, the cecum was exteriorized through a small mid-
line laparotomy and a piece of tumor tissue derived from CT26/
Fluc cells was sutured to the cecal surface with a single Maxon 
7/0 suture, leaving the tumor tissue buried in a ‘pouch’ consist-
ing of a double cecal wall on each side. After implantation, the 
abdominal wall was closed in two layers with Dexon 5/0. Ten 
days after cecal implantation of the colon tumor, the groups of 
mice were randomly assigned to receive one of the following 
two treatments (n = 6 per group): (a) tail vein injections of an 
empty pSUPER vector with FuGene 6 transfection reagent (Roche, 
Seoul, Korea) at intervals of 4 days, and (b) tail vein injections 
of KITEININ shRNA with FuGene 6 at intervals of 4 days. The 
KITENIN shRNA was a mixture of KITENIN shRNA2 and KIT-
ENIN shRNA5, administered at doses of 100 μg in a volume of 
100 μL per injection for each mouse as previously described (14). 
To facilitate delivery of the vectors or shRNA in vivo, the Fugene 
6 transfection reagent was applied according to the manufac-
turer’s protocol. Each mouse was analyzed by optical imaging 
at intervals of 4 days after tumor implantation.
Adjuvant therapy model
The adjuvant therapy model was based on the orthotopic mouse 
colon cancer model described earlier. When the total flux of the 
implanted tumor was determined by the in vivo imaging system 
(IVIS) to have exceeded 5 × 10
6, a cecectomy (tumor resection) 
was performed under general anesthesia. The abdomen was 
prepared for sterile surgery, and a median incision was made. 
The colon was exposed after careful dissection and hemostasis 
of peritoneal adhesion. The cecum was fully resected using a sur-
gical clip as reported by Kuo et al. (17). The bowel was replaced 
in the abdominal cavity, and the wound was closed in two layers. 
We selected mice with bioluminescence signal intensities be-
low 3 × 10
5 photons/sec when imaged one day after tumor re-
section, and randomly assigned them to three groups: surgery 
only, CPT-11 (Irinotecan hydrochloride, Pfizer, New York, NY, 
USA) treatment, or KITENIN shRNA treatment group. CPT-11 
is an effective chemotherapeutic agent for colorectal cancer (18, 
19) and we used CPT-11 as a reference tool to examine the effi-
cacy of KITENIN shRNA. At the time of randomization, each 
mouse expressed only a background bioluminescence signal 
and differences in signal intensities among the three groups were 
not significant (P = 0.806, Table 1). In retrospective analysis of 
the preoperative signals in the three randomized groups, there 
were no differences in signal intensities among them (P = 0.767, 
Table 1). A total dose of 100 μg of KITENIN shRNA was given by 
intravenous (i.v.) injection on postoperative days 2, 5, and 8, and 
CPT-11 (40 mg/kg) was given by intraperitoneal (i.p.) injection 
Table 1. Bioluminescence signal intensities before and after tumor resection in the 
adjuvant therapy model
Mean Bioluminescence Signals (n = 8)
P value
Control CPT-11
KITENIN  
shRNA
Before resection 1.55E+07 1.74E+07 1.16E+07 0.767
After resection 1.59E+05 1.78E+05 1.90E+05 0.806Hwang J-E, et al.  •  KITENIN shRNA Therapy in Orthotopic Mouse Colon Cancer Model
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on postoperative days 2, 5, and 8. Each group was composed of 
8 mice. One mouse from the control group, two from the CPT-11 
treatment group, and two from the KITENIN shRNA treatment 
group died from postoperative complications within five days 
after randomizations. Seven mice from the control group and 
six mice each from the CPT-11 and KITENIN shRNA treatment 
groups were finally analyzed. Tumor recurrence in mice was 
monitored weekly using in vivo bioluminescence imaging (BLI). 
All surviving animals were sacrificed on the ninth postoperative 
week.
Histological analysis
At 4 weeks after tumor implantation, the mice from each group 
in primary therapy model were sacrificed. Specimens from the 
tumor bed, peritumoral lymphovascular structure, and liver were 
fixed with 4% formaldehyde in PBS, dehydrated with ethanol, 
embedded in paraffin blocks, sectioned in 4 μm increments and 
stained with hematoxylin-eosin and KITENIN.
Statistical analysis
Differences in bioluminescence signals were analyzed by a Mann-
Whitney test. Differences in the incidence of mucosal invasion, 
peritumoral lymphovascular invasion, and liver metastasis were 
analyzed by two-way Fisher’s exact and chi-squared tests. The 
difference in tumor volume was analyzed by a Student’s two-
tailed t-test. The survival curves were calculated according to 
the Kaplan-Meier Method and the differences in survival were 
analyzed using the log-rank test. In all cases, P < 0.05 was con-
sidered to be significant. 
RESULTS
Suppression of progression and metastasis of the primary 
tumor with KITENIN shRNA in an orthotopic mouse colon 
cancer model
Since observation that KITENIN shRNA markedly suppresses 
KITENIN expression ex vivo and in vivo was reported previously 
(14), this study evaluated the effects of the intravenous adminis-
tration of KITENIN shRNA on tumor burden, invasion, and me-
tastasis using a clinically relevant orthotopic mouse colon can-
cer model. Fig. 1A shows a typical example of the assessment of 
signal intensity using in vivo BLI. All mice in both groups showed 
tumor progression as evidenced by increasing bioluminescence 
signal intensities, but the administration of KITENIN shRNA sub-
stantially delayed tumor growth in comparison with the control 
vector-treated group. At day 20, 24, and 28 after tumor implan-
tation, the KITENIN shRNA treatment group showed significant 
signal inhibition compared to the control group (P < 0.05; Fig. 1B). 
  When the mice were sacrificed for autopsy on day 28 after or-
thotopic implantation, metastatic mass of the liver was often 
observed in the control group (Fig. 2A). In the mice treated with 
KITENIN shRNA, the tumor growth tended to be confined to 
the region of the cecum where the tumor had been implanted 
and exhibited slower growth. Treatment with KITENIN shRNA 
resulted in a 64% reduction in tumor volume relative to vehicle 
control mice (P = 0.028; n = 6 per group, Table 2). Histological 
findings of the primary tumor, peritumoral lymphovascular struc-
ture, and liver were assessed in tissue sections for the evaluation 
of tumor invasion and metastasis. Mucosal invasion was detect-
ed in two of the six KITENIN shRNA-treated mice and in five of 
the six control mice (P = 0.079; Table 2, Fig. 2B-D). Tumor em-
bolus in the lymphovascular structure was detected in one of the 
six KITENIN shRNA-treated mice and in three of the six control 
mice (P = 0.221; Table 2, Fig. 2E, F). Metastatic nodules in the liver 
were observed in three of the six control mice and not observed 
in KITENIN shRNA-treated mice (P = 0.046; Table 2, Fig. 2G, H). 
	 4	 8	 12	 16	 20	 	24	 28
1.0
0.8
×
	
1
0
8
0.6
0.4
0.2
Control	
No.	164
Davs	after	tumor	implantation
KITENIN	
shRNA	
No.	170
A
B
B
i
o
l
u
m
i
n
e
s
c
e
n
c
e
	
s
i
g
n
a
l
	
(
P
/
s
e
c
/
c
m
2
/
s
r
)
Days	after	tumor	implantation
Control
KITENIN	shRNA	teatment
0	 4	 8	 12	 16	 20	 24	 28
60,000
50000
40000
30000
20000
10000
0
Fig. 1. Quantitative photon counting analysis of the progression of orthotopically im-
planted tumors. (A) Detection of the progression process in control and KITENIN shR-
NA treatment groups. (B) Quantitative analysis of the progression process in control       
(    ) and KITENIN shRNA treatment groups (    ) (n = 6). Points, mean of six mice per 
group; bars, SE. 
Table 2. Biometric analysis of control and KITENIN shRNA-treated tumors in the pri-
mary therapy model
Invasion  
to mucosa
Lymphovas-
cular  
tumor emboli
Liver  
metastasis
Tumor volume 
(mm
3)
Control 5/6 3/6 3/6 2,392.0 ± 570.5
KITENIN shRNA 2/6 1/6  0/6*    869.1 ± 229.3*
*P < 0.05, compared with control tumors according to χ2 test (for incidence) and Stu-
dent’s two-tailed t test.Hwang J-E, et al.  •  KITENIN shRNA Therapy in Orthotopic Mouse Colon Cancer Model
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Adjuvant therapeutic effect of KITENIN shRNA in an 
orthotopic mouse colon cancer model
The data above confirmed that KITENIN shRNA treatment is 
effective for the treatment of established mouse colon cancer. 
Next, we hypothesized that adjuvant KITENIN shRNA treatment 
would reduce recurrence and prolong survival following surgi-
cal resection of the colon tumor mass in mice. To test this hy-
pothesis, we established an animal model simulating an adju-
vant treatment setting. Tumor recurrence in mice was monitored 
weekly using in vivo BLI (Fig. 3A). Recurrence-free survival data 
according to treatment group was given in Fig. 3B. The KITENIN 
shRNA treatment group achieved superior results compared to 
the control group (P = 0.044). There were no differences in re-
currence-free survival between the CPT-11 treatment and KIT-
ENIN shRNA treatment groups or between the CPT-11 treatment 
and control groups. The recurrence rates in the control group, 
CPT-11 treatment group, and KITENIN shRNA treatment group 
were 71.4% (5 of 7), 50.0% (3 of 6), and 16.7% (1 of 6), respectively. 
To examine whether the tumor suppression effect of KITENIN 
shRNA treatment could yield a survival benefit, survival within 
the three groups was calculated by Kaplan-Meier analysis. At 
the end of the experimental period, there were 2, 3, and 5 survi-
vors in the control, CPT-11, and KITENIN shRNA-treated mouse 
groups, respectively. Mice treated with KITENIN shRNA showed 
a tendency toward increased survival compared to the control 
mice (P = 0.074; Fig. 3C).
 
DISCUSSION
The primary aim of the present study was to investigate the ef-
fects of KITENIN knockdown by intravenous administration of 
KITENIN shRNA after primary tumor establishment, or postop-
eratively as an adjuvant treatment in an orthotopic mouse colon 
cancer model. Suitable animal models that mimic the clinical 
situation are essential to develop new therapeutic strategies. 
Fidler (20, 21) and Morikawa et al. (22) reported that orthotopic 
implantation was necessary to induce metastasis of colon can-
cer in mice, i.e. a higher rate of liver metastasis by colon cancer 
was observed when tumors were implanted on the cecum com-
pared with subcutaneous implantation. Using BLI, tumors in 
the same animal can be sequentially visualized and the tumor 
volume can be quantified, as reported for various tumor models 
(23-29). Previous studies have validated the use of BLI in a mu-
rine orthotopic colorectal cancer metastasis model and report-
ed strong correlations between the bioluminescent signal inten-
sity and tumor mass (24, 30). The bioluminescent signal inten-
Fig. 2. Macroscopic and microscopic appearance of tumor growth after orthotopic implantation. (A) Necropsy pictures are shown. A red circle outlines the implanted tumor and 
a blue circle outlines the hepatic nodule. (B) H&E section of a tumor-bearing cecum. (C, D) Higher magnifications of the black box in B showing tumor invasion into the mucosa 
(control group) or tumor growth not penetrating the mucosa and submucosa (KITENIN shRNA-treated group). M, mucosa; SM, submucosa; Tm, tumor. Asterisks in D indicate 
invasion into the adjacent colonic crypt. (E, F) Peritumoral lymphovascular tumor embolus (TE). (G, H) Metastatic nodule of the liver. Black arrows indicate a subcapsular tumor 
nodule in the liver.
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sity is depth-dependent, resulting in a higher signal for superfi-
cial lesions than for deeper lesions. The other major limitation 
of BLI is that the planar nature of the images impedes accurate 
3-dimensional localization of the signal (30). Nevertheless, BLI 
is a sensitive and powerful tool for high-throughput longitudi-
nal monitoring of tumor load in small animals and allows for the 
implementation of more advanced orthotopic tumor models in 
therapy intervention studies. In the present study, orthotopic 
mouse models for colon cancer were established successfully 
by using firefly luciferase-expressing CT-26 murine adenocarci-
noma cells. In the primary therapy model, administration of 
KITENIN shRNA substantially delayed growth of the established 
tumor and reduced the incidence of liver metastasis in compar-
ison with the control vector-injected group. These data recon-
firm our previous report that KITENIN suppression by shRNA 
inhibits tumor progression and liver metastasis in a subcutane-
ous tumor model (14). In the adjuvant therapy model, KITENIN 
shRNA treatment achieved superior results compared to the con-
trol group in terms of recurrence-free survival rate (Fig. 3B). Mice 
treated with KITENIN shRNA demonstrated a tendency toward 
increased survival compared to control mice (Fig. 3C). At the 
time of randomization, there were no differences in biolumines-
cence signal intensities among the three groups (P = 0.806). This 
allows us to exclude biases in residual disease among the three 
groups, which supports the reliability of the estimation of the 
effectiveness of the treatments in an adjuvant setting. In our ad-
juvant experimental model, all mice with recurrent tumor died 
during the follow-up period, but not of the mice without tumor 
recurrence. The recurrence rate (death rate) was lower in the 
KITENIN shRNA treatment group (16.7%) compared to the CPT-
11 treatment group (50.0%), although the difference was not sta-
tistically significant (P = 0.195). These results suggest that gene 
therapy with shRNA targeting KITENIN could be as useful as 
chemotherapy for the treatment of colon cancer. 
  We recently examined the expression of KITENIN in paraffin-
embedded samples of primary colon tumors, adjacent normal 
Fig. 3. Tumor recurrence was monitored weekly using in vivo bioluminescence imaging (BLI) and recurrence-free survival was estimated. (A) Detection of recurrence after tu-
mor resection by in vivo BLI. PI#1, post-implantation 1; BOP, before operation. (B, C) Recurrence-free survival and overall survival according to treatment in the adjuvant treat-
ment model. Time scale relates to days after tumor resection. 
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colonic mucosa, metastatic mass of the liver and lymph node 
from the patients with colon cancer by immunohistochemical 
staining (15). Compared with the expression in the adjacent nor-
mal mucosa, KITENIN was highly expressed in the tumor. There 
was a positive correlation between the expression level of KIT-
ENIN and advanced stages of human colon cancer. Also, KIT-
ENIN expression in metastatic lymph nodes and liver masses 
was comparable with that of colon tumors in stage IV colon can-
cer. These results suggested that gene therapy using an anti-KIT-
ENIN strategy might be effective for human colon cancer. 
  In summary, this study demonstrated that systemic adminis-
tration of KITENIN shRNA inhibits tumor progression, distant 
metastasis, and recurrence in orthotopic mouse colon cancer 
models. These results suggest that shRNA targeting KITENIN 
has the potential to be an effective tool for the treatment of co-
lon cancer in both adjuvant and metastatic setting. 
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Intravenous KITENIN shRNA Injection Suppresses Hepatic Metastasis and 
Recurrence of Colon Cancer in an Orthotopic Mouse Model
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and Ik-Joo Chung
Despite the development of chemothepeutic agents colon cancer, the prognosis of recurred or metastatic colon cancer has been 
poor. KITENIN promotes invasion and metastasis in colon cancer. We found that KITENIN knockdown by intravenous administration 
of shRNAs substantially delayed the tumor growth and reduced the extent of tumor recurrence in a mouse colon cancer model. 
Our results suggest that shRNA targeting KITENIN can be the potentially effective method for the treatment of colon cancer.